Chemotherapy News and Research

Latest Chemotherapy News and Research

Breast cancer patients who achieve pathological complete response have better outcomes

Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP).

12 Oct 2009

New law lets injured or ill college students keep parents' health insurance

A new federal law took effect Friday, allowing seriously ill or injured college students to keep their parents' insurance for up to a year while they take time off from school.

12 Oct 2009

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®.

12 Oct 2009

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

MedaSorb Technologies Corporation and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors.

9 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

OncoGenex Pharmaceuticals, Inc., announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

9 Oct 2009

TargetEx to be the coordinator for CancerGrid consortium

TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

9 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

Emisphere Technologies announces commercial launch of oral Eligen B12

Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

8 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

Ipsen and Spirogen sign new licensing agreement for development of SJG-136 anticancer agent

Ipsen and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder SJG-136 (now known as SG2000).

8 Oct 2009

Study discusses possible genetic effects of radiation and cancer drug exposures on future generations

Researchers at the University of Oklahoma Health Sciences Center are helping to lead a massive international study on the possible genetic effects of radiation and cancer drug exposures on future generations.

8 Oct 2009

New study finds rare type of head and neck cancer caused by HPV

An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

8 Oct 2009

Study suggest childhood cancer survivors are less likely to get married

Childhood cancer survivors typically suffer from the long-term effects of cancer treatment on physical health, and results of a new study suggest that social implications also exist, which may affect their chance of an "I do" at the altar.

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

Genomic Health to present study results of Oncotype DX multi-gene expression test

Genomic Health, Inc. today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California.

8 Oct 2009

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Breast cancer patients who achieve pathological complete response have better outcomes

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

New law lets injured or ill college students keep parents' health insurance

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

TargetEx to be the coordinator for CancerGrid consortium

Manchester scientists test radioimmunotherapy in early phase clinical trials

Emisphere Technologies announces commercial launch of oral Eligen B12

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

New cancer drugs boost drug spending

Ipsen and Spirogen sign new licensing agreement for development of SJG-136 anticancer agent

Study discusses possible genetic effects of radiation and cancer drug exposures on future generations

New study finds rare type of head and neck cancer caused by HPV

Study suggest childhood cancer survivors are less likely to get married

Entest BioMedical applies for Phase II grant from National Cancer Institute

Genomic Health to present study results of Oncotype DX multi-gene expression test

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in